Citation:Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al 2009

Citation

Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 2009 Aug 18;101(4):715-21 Available from: http://www.ncbi.nlm.nih.gov/pubmed/19603018.

Critical appraisals

• Assign a critical appraisal

Cited by

1. Molecular pathology and biomarkers – implications for systemic therapy